100 Days Mission: 4th Implementation Report and Scorecard

Together with the International Pandemic Preparedness Secretariat, we developed the 100 Days Mission Scorecard to provide a quantifiable state of preparedness for future pandemics. This year’s Scorecard now includes the addition of data for Chikungunya and Mpox to more closer align with WHO’s updated pathogen prioritisation framework

New data from the 2024 Scorecard shows:

• Limited new approvals: Only six new diagnostic tests (for Chikungunya and Ebola) and one therapeutic (Ebola monoclonal antibody treatment) were approved, with no new vaccines for priority pathogens from Scorecard 1.0.
• Early pipeline progress: Seven vaccines entered Phase 1 trials, but only one advanced to Phase 3. The therapeutics pipeline saw just two candidates progress to phase 1 and 2 trials, highlighting limited development for non-COVID pathogens.
• Declines in funding: Non-COVID DTV funding fell by 31% from 2022 to 2023, with sharp decreases for Rift Valley Fever (92%), MERS (84%), and SARS (77%), while overall R&D funding for priority pathogens remains reactive.
• Over-reliance on dominant funding sources: The U.S. government accounted for 60% of global R&D funding (68% excluding COVID-19), highlighting the need for other funders to step in and share both investments and benefits.